Literature DB >> 31666975

Novel USP9X variants in two patients with X-linked intellectual disability.

Yoshinori Tsurusaki1,2, Yukiko Kuroda3, Yasuko Yamanouchi4, Eisuke Kondo5, Kazunobu Ouchi5, Yuichi Kimura1, Yumi Enomoto1, Noriko Aida6, Mitsuo Masuno4,5, Kenji Kurosawa3.   

Abstract

USP9X variants have been reported in patients with X-linked intellectual disability. Here, we report two female patients with intellectual disability and pigment abnormalities along Blaschko lines. Targeted resequencing identified two novel heterozygous variants, c.4068_4072del (p. (Leu1357Tyrfs*12)) and c.1201C>T (p. (Arg401*)), in USP9X. Our findings provide further evidence that USP9X variants cause intellectual disability.
© The Author(s) 2019.

Entities:  

Keywords:  Genetic testing; Genetics research

Year:  2019        PMID: 31666975      PMCID: PMC6804943          DOI: 10.1038/s41439-019-0081-7

Source DB:  PubMed          Journal:  Hum Genome Var        ISSN: 2054-345X


Intellectual disability (ID) is characterized by significant limitations in both intellectual functioning and adaptive behavior, with onset before the age of 18 years, and is commonly defined by an IQ score of <70[1,2]. ID occurs in ~1–3% of the population worldwide[1]. To date, almost 100 causative genes have been reported for X-linked ID (XLID)[3]. Variants in USP9X, which is located at Xp11.4, have been suggested to cause various types of cancer, female-restricted X-linked syndromic mental retardation-99 (MIM 300968), and X-linked recessive mental retardation-99 (MIM 300919). USP9X encodes ubiquitin-specific protease 9×, which is highly expressed in the mouse brain and plays important roles in nervous system development, stabilization of myeloid leukemia cell differentiation protein (MCL1) in human follicular lymphomas and diffuse large B-cell lymphomas, and tumor cell survival[4-6]. In this study, we identified novel USP9X variants in two female patients with XLID by using targeted resequencing. Patient 1 is a 4-year-old girl who is the second child of healthy and nonconsanguineous parents. She was delivered at 37 weeks of gestation with a birth weight of 2278 g (−1.1 SD), a length of 47 cm (−0.1 SD), and an occipital frontal circumference of 30.5 cm (−1.5 SD). She was able to walk unsupported by 23 months. She began speaking in recognizable words at 2 years of age, at which point she also began to show signs of moderate-to-severe ID. The patient was referred to Kanagawa Children’s Medical Center because of developmental delay at 2 years of age. At the time of referral, she was 82.7-cm tall (−1.0 SD), weighed 13.4 kg (1.6 SD), and had an occipital frontal circumference of 46.4 cm (−0.7 SD). She had dysmorphic features consisting of upswept and curly hair, facial asymmetry, prominent forehead, bitemporal narrowing, short palpebral fissures, prominent nose with flared ala nasi, smooth philtrum, thin upper lip, full cheeks, dysplastic ears, tapering fingers, and Blaschko lines (Fig. 1a, b). She spoke several individual words and exhibited autistic behavior, including repetitive and stereotyped movements. At 3 years and 11 months of age, she developed obesity. She was 98-cm (0 SD) tall and weighed 18.6 kg (1.9 SD), and her body mass index was 19.4, which is >97th percentile for age. Her karyotype is 46,XX.
Fig. 1

Patients with USP9X variants.

a Patient 1 at 4 years of age. The patient exhibited upswept and curly hair, facial asymmetry, prominent forehead, bitemporal narrowing, short palpebral fissures, prominent nose with flared ala nasi, smooth philtrum, thin upper lip, full cheeks, and dysplastic ears. b Patient 1 at 4 years of age. The patient had tapered fingers. c Patient 2 at 18 months of age. Pigment changes along Blaschko lines bilaterally on the upper arms (d) and neck

Patients with USP9X variants.

a Patient 1 at 4 years of age. The patient exhibited upswept and curly hair, facial asymmetry, prominent forehead, bitemporal narrowing, short palpebral fissures, prominent nose with flared ala nasi, smooth philtrum, thin upper lip, full cheeks, and dysplastic ears. b Patient 1 at 4 years of age. The patient had tapered fingers. c Patient 2 at 18 months of age. Pigment changes along Blaschko lines bilaterally on the upper arms (d) and neck Patient 2 is the first child of a 40-year-old primigravid mother and a nonconsanguineous 41-year-old father. Pregnancy was achieved by artificial insemination by using the husband’s sperm, and labor and delivery were uneventful. Owing to the advanced maternal age, prenatal cytogenetic analysis by using G-banding was performed on amniocentesis, and the results were normal. The maternal grandfather’s sister had a history of retinitis pigmentosa. The proposita was born at 41 weeks and 1 day of gestation. The newborn had a birth weight of 2968 g (−0.5 SD), a length of 48.3 cm (−0.9 SD), and a head circumference of 34.2 cm (0.4 SD). Apgar scores were 8 at 1 min and 9 at 5 min. During the early neonatal period, bilateral cryptotia, congenital hearing impairment as detected by auditory brain-stem response (rt-70 dB, lt-50 dB), and right muscular torticollis were noted. Bilateral clasped thumbs were identified at 2 months of age and had improved by 11 months of age. She was first evaluated by Kawasaki Medical School Hospital at 9 months of age because of developmental delay. The main clinical manifestations included epicanthus, telecanthus, short columella, depressed nasal tip, bilateral low-set and posteriorly rotated ears, overfolded helices, bifid uvula, umbilical hernia, and bilateral overlapping toes (T2–3, T4–5). At the time of evaluation, she was 73.4 cm (1.4 SD) in height, weighed 8465 g (0.3 SD), and had a head circumference of 44.8 cm (0.8 SD). Her muscle tone was normal. Pigment changes along Blaschko lines appeared bilaterally on the upper arms at 12 months and on the neck at 18 months (Fig. 1c, d). She suffered from recurrent otitis media with effusion after 12 months of age. She was able to lift her head at 4 months of age, sat alone at 8 months, babbled at 12 months, and walked unaided at 17 months. Her developmental quotient was 71 at 17 months. At 18 months, her height was 80.8 cm (0.5 SD), and her weight was 9.9 kg (0 SD). Ophthalmological evaluations revealed astigmatism, hyperopia, and normal fundi. Ultrasonographic examination of the heart and abdomen showed normal findings. Other normal laboratory tests included thyroid function (free T4, free T3), somatomedin-C, serum chemistries, immunoglobulins, complete blood counts, blood gas analysis, and urinalysis. Clinical information was obtained after obtaining written informed consent from the patients’ families. The institutional review board of Kanagawa Children’s Medical Center approved this study. Genomic DNA was extracted from both patients’ peripheral blood by using the QIAcube (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. Targeted resequencing was performed for the two affected patients. Genomic DNA was captured by the TruSight One Sequencing Panel (Illumina, Inc., San Diego, CA, USA) and was sequenced on a MiSeq platform (Illumina) with 151-bp paired-end reads, as previously described[7]. The candidate variant was confirmed by Sanger sequencing. Targeted resequencing identified two heterozygous variants in USP9X (NM_001039590.2): c.4068_4072del (p.(Leu1357Tyrfs*12)) in patient 1 and c.1201C>T (p.(Arg401*)) in patient 2. These variants were not present in the NHLBI-Exome Sequencing Project 6500, the 1000 Genomes Project, dbSNP138, the Human Genetic Variation Database or in our in-house Japanese exome database. Sanger sequencing confirmed that these variants had occurred de novo (Fig. 2).
Fig. 2

USP9X variants.

Novel heterozygous variants identified in two female patients. USP9X is predicted to contain a ubiquitin-specific protease domain, as determined by SMART (http://smart.embl-heidelberg.de/). Electropherogram for each patient and her parents

USP9X variants.

Novel heterozygous variants identified in two female patients. USP9X is predicted to contain a ubiquitin-specific protease domain, as determined by SMART (http://smart.embl-heidelberg.de/). Electropherogram for each patient and her parents Here, we report two female patients with heterozygous variants in USP9X who exhibited ID and pigment abnormalities along Blaschko lines (Supplementary Table S1). These two USP9X variants are truncating variants, resulting in a premature stop codon (Fig. 2). Reijnders et al. reported de novo loss-of-function variants of USP9X in 17 female patients[8]. Au et al. also reported de novo pericentric inversion resulting in a 0.326-Mb deletion of the USP9X 5′ UTR and a de novo truncating variant in two female patients[9]. Homan et al. reported two maternally inherited missense variants and a truncating variant of USP9X in three male patients[10]. This truncating variant is located in the last exon, and as such, the mRNA presumably escapes nonsense-mediated decay. Thus, USP9X alterations in female-restricted X-linked syndromic mental retardation-99 may confer loss-of-function effects. On the other hand, USP9X alterations in X-linked recessive mental retardation-99 may confer hypomorphic or a milder form of loss-of-function effects. The clinical features of our two patients were compared with previously reported female patients with variants in USP9X (Supplementary Table S1). All patients with USP9X variants exhibited ID. Some patients with ID also showed pigment abnormalities along Blaschko lines, including our patients. Dental abnormalities, asymmetric hypomastia, heart defects, urogenital abnormalities, scoliosis, postaxial polydactyly, seizures, hypotonia, and recurrent respiratory tract infections were observed in some of the previously reported patients but not in our patients. Further analysis is required to determine the phenotype–genotype correlation. Endogenous USP9X localizes to the primary cilium; however, this localization was significantly decreased when USP9X expression was knocked down in fibroblasts by using siRNA[8]. Female heterozygous knockout mice (Nes-Usp9x) were normal at birth and survived to adulthood[6]. A small reduction in the hippocampal area was observed in adult female knockout mice (Emx1-Usp9x)[6]. However, no reduction in the hippocampal area was observed in our patients. In contrast, male hemizygous knockout mice (Nes-Usp9x ) died within 24 h of birth[6]. In conclusion, we identified heterozygous USP9X variants in two female patients. Our report provides further evidence that USP9X variants are associated with XLID. Supplementary Table S1
  10 in total

Review 1.  Genetic studies in intellectual disability and related disorders.

Authors:  Lisenka E L M Vissers; Christian Gilissen; Joris A Veltman
Journal:  Nat Rev Genet       Date:  2015-10-27       Impact factor: 53.242

2.  USP9X, a Putative Tumor Suppressor Gene, Exhibits Frameshift Mutations in Colorectal Cancers.

Authors:  Yun Sol Jo; Min Sung Kim; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2016-10-21       Impact factor: 3.201

3.  Mutations in USP9X are associated with X-linked intellectual disability and disrupt neuronal cell migration and growth.

Authors:  Claire C Homan; Raman Kumar; Lam Son Nguyen; Eric Haan; F Lucy Raymond; Fatima Abidi; Martine Raynaud; Charles E Schwartz; Stephen A Wood; Jozef Gecz; Lachlan A Jolly
Journal:  Am J Hum Genet       Date:  2014-03-06       Impact factor: 11.025

Review 4.  Epigenetic Etiology of Intellectual Disability.

Authors:  Shigeki Iwase; Nathalie G Bérubé; Zhaolan Zhou; Nael Nadif Kasri; Elena Battaglioli; Marilyn Scandaglia; Angel Barco
Journal:  J Neurosci       Date:  2017-11-08       Impact factor: 6.167

5.  Two females with mutations in USP9X highlight the variable expressivity of the intellectual disability syndrome.

Authors:  P Y B Au; L Huang; S Broley; L Gallagher; E Creede; D Lahey; S Ordorica; K Mina; K M Boycott; G Baynam; D A Dyment
Journal:  Eur J Med Genet       Date:  2017-04-01       Impact factor: 2.708

Review 6.  X-linked intellectual disability update 2017.

Authors:  Giovanni Neri; Charles E Schwartz; Herbert A Lubs; Roger E Stevenson
Journal:  Am J Med Genet A       Date:  2018-04-25       Impact factor: 2.802

7.  De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations.

Authors:  Margot R F Reijnders; Vasilios Zachariadis; Brooke Latour; Lachlan Jolly; Grazia M Mancini; Rolph Pfundt; Ka Man Wu; Conny M A van Ravenswaaij-Arts; Hermine E Veenstra-Knol; Britt-Marie M Anderlid; Stephen A Wood; Sau Wai Cheung; Angela Barnicoat; Frank Probst; Pilar Magoulas; Alice S Brooks; Helena Malmgren; Arja Harila-Saari; Carlo M Marcelis; Maaike Vreeburg; Emma Hobson; V Reid Sutton; Zornitza Stark; Julie Vogt; Nicola Cooper; Jiin Ying Lim; Sue Price; Angeline Hwei Meeng Lai; Deepti Domingo; Bruno Reversade; Jozef Gecz; Christian Gilissen; Han G Brunner; Usha Kini; Ronald Roepman; Ann Nordgren; Tjitske Kleefstra
Journal:  Am J Hum Genet       Date:  2016-01-28       Impact factor: 11.025

8.  Loss of Usp9x disrupts cortical architecture, hippocampal development and TGFβ-mediated axonogenesis.

Authors:  Shane Stegeman; Lachlan A Jolly; Susitha Premarathne; Jozef Gecz; Linda J Richards; Alan Mackay-Sim; Stephen A Wood
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

9.  USP9X destabilizes pVHL and promotes cell proliferation.

Authors:  Cong Zhang; Zuohan Peng; Minglu Zhu; Penglong Wang; Xiao Du; Xiang Li; Yu Liu; Yan Jin; Michael A McNutt; Yuxin Yin
Journal:  Oncotarget       Date:  2016-09-13

10.  Novel COL4A1 mutation in a fetus with early prenatal onset of schizencephaly.

Authors:  Yota Sato; Jun Shibasaki; Noriko Aida; Kazuya Hiiragi; Yuichi Kimura; Moe Akahira-Azuma; Yumi Enomoto; Yoshinori Tsurusaki; Kenji Kurosawa
Journal:  Hum Genome Var       Date:  2018-04-24
  10 in total
  1 in total

1.  Missense variant contribution to USP9X-female syndrome.

Authors:  Lachlan A Jolly; Euan Parnell; Alison E Gardner; Mark A Corbett; Luis A Pérez-Jurado; Marie Shaw; Gaetan Lesca; Catherine Keegan; Michael C Schneider; Emily Griffin; Felicitas Maier; Courtney Kiss; Andrea Guerin; Kathleen Crosby; Kenneth Rosenbaum; Pranoot Tanpaiboon; Sandra Whalen; Boris Keren; Julie McCarrier; Donald Basel; Simon Sadedin; Susan M White; Martin B Delatycki; Tjitske Kleefstra; Sébastien Küry; Alfredo Brusco; Elena Sukarova-Angelovska; Slavica Trajkova; Sehoun Yoon; Stephen A Wood; Michael Piper; Peter Penzes; Jozef Gecz
Journal:  NPJ Genom Med       Date:  2020-12-09       Impact factor: 8.617

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.